Views & Analysis

Views & Analysis
NICE

NICE numbers at 20

Leela Barham takes a look at NICE’s stats on Technology Appraisals to see how the agency has changed over it’s 20-year history and what the future might hold.

Views & Analysis
Optimising market access for biosimilars

Optimising market access for biosimilars

We speak to Sandoz’s global head of biopharmaceuticals, Stefan Hendriks, about the remaining challenges in market access for biosimilars and what the future could hold for this still-bu

Views & Analysis
Nine for 2019 Opportunities for pharma

Nine for 2019: Challenges impacting pharma

As we move close to 2019’s halfway point, it’s time to reflect on the issues that are shaping the pharmaceutical industry for this year and beyond.